Marker Therapeutics, Inc. (MRKR) · Nov 19, 2026 · Other events

Marker Therapeutics grant adds $16.2M for MT-601 lymphoma trial

$16.2M grant — Non-dilutive CPRIT award supporting planned Phase 2 APOLLO study

Marker Therapeutics won a $16.2M CPRIT grant to support MT-601’s planned Phase 2 lymphoma study, easing funding pressure but not proving efficacy.

Marker is a cash-constrained, clinical-stage immuno-oncology company trying to move MT-601 from encouraging Phase 1 lymphoma data into a planned Phase 2 study. Its latest 10-Q reported about $9.4 million of cash and a runway only into the second quarter of 2027 assuming no additional grant proceeds, while also flagging substantial doubt about continuing as a going concern.

The funding materially improves the near-term development story. CPRIT awarded Marker $16.2 million, more than the company held in cash at September 30, and designated the money for advancing MT-601 in the planned Phase 2 APOLLO study for patients with large B-cell lymphoma after CD19 CAR-T treatment. 〔0〕 This is meaningful because it can fund the central clinical program without immediately relying on another dilutive equity raise.

Current figureComparison
CPRIT grant (Grant announcement)$16.2MCash: $9.4M
Phase 1 objective response rate (Clinical results)66%12 evaluable NHL patients
Phase 1 complete response rate (Clinical results)50%12 evaluable NHL patients

The grant validates the program’s fundability, not its clinical success. The award followed a competitive review that considered scientific merit, clinical strategy, regulatory issues, manufacturing, intellectual property and commercial potential, but it does not change MT-601’s status as an investigational therapy. The clinical evidence remains early: the cited response rates came from only 12 evaluable non-Hodgkin lymphoma patients, and the Phase 2 study is still described as planned.

The next proof point is still clinical execution. Marker says it expects to provide updated clinical results later in 2026. 〔1〕 Those data, rather than the grant itself, will determine whether the promising Phase 1 signal can support a larger development effort.

Bottom line: This is a clearly important financing and execution step: Marker has secured non-dilutive capital large enough to materially ease the funding burden around MT-601’s planned lymphoma Phase 2. It advances the business story, but leaves the core efficacy question unanswered until the next clinical update.

What to watch next

Updated MT-601 clinical results later in 2026

Original filing on SEC EDGAR

More Marker Therapeutics, Inc. news

Marker Therapeutics grant adds $16.2M for MT-601 lymphoma trial | MRKR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.